Tgtx stocktwits

Investor Relations | TG Therapeutics, Inc. Investor Relations TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TGTX - TG Therapeutics Inc Stock quote - CNNMoney.com Find real-time TGTX - TG Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. NASDAQ:TGTX TG Therapeutics Stock Price, Forecast & News TG Therapeutics Inc (NASDAQ:TGTX) issued its quarterly earnings results on Tuesday, March, 3rd. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.01. The biopharmaceutical company earned $0.04 million during the quarter, compared to the consensus estimate of

TGTX Stock Summary. Of note is the ratio of Tg Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 3.99% of US stocks have a lower such ratio. TGTX's price/sales ratio is 7,355.79; that's higher than the P/S ratio of 99.95% of US stocks.

TG Therapeutics Inc (NASDAQ:TGTX) issued its quarterly earnings results on Tuesday, March, 3rd. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.01. The biopharmaceutical company earned $0.04 million during the quarter, compared to the consensus estimate of TGTX - TG Therapeutics Inc. • BioPharmCatalyst NewsSee all news. 09 March 2020 TG Therapeutics Announces Data Presentations at the Upcoming American Academy of Neurology 72nd Annual Meeting. NEW YORK, March 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that abstracts featuring ublituximab, the Company's novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing TGTX: TG Therapeutics, Inc. - Detailed Estimates - Zacks.com TGTX: TG Therapeutics, Inc. Detailed Estimate. Get the latest Detailed Estimate from Zacks Investment Research. TGTX -- Is Its Stock Price A Worthy Investment? Learn More. TGTX Stock Summary. Of note is the ratio of Tg Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 3.99% of US stocks have a lower such ratio. TGTX's price/sales ratio is 7,355.79; that's higher than the P/S ratio of 99.95% of US stocks.

Stock analysis for TG Therapeutics Inc (TGTX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. TG Therapeutics, Inc. is a clinical

Read the latest StockTalks, investment ideas, and community discussion on TG Therapeutics, Inc. (TGTX). TG Therapeutics, Inc. Common Stock (TGTX) Stock Quotes ... TG Therapeutics, Inc. Common Stock (TGTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. TGTX | Stock Snapshot - Fidelity Apr 03, 2020 · Stock quote and company snapshot for TG THERAPEUTICS INC (TGTX), including profile, stock chart, recent news and events, analyst opinions, and research reports. StockTwits Read live tweets from the financial and investing community about the stock you're interested in. TGTX Stock Price and Chart — NASDAQ:TGTX — TradingView